Italy accounts for 3.3% share of global clinical trial activity in 2020 – Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Italy accounts for 3.3% share of global clinical trial activity in 2020

07 May 2021 (Last Updated May 7th, 2021 21:45)

Italy has accounted for a 3.3% share of the global clinical trials activity in 2020, registering a decrease when compared with the last ten-year average of a 4.8% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in Italy

Industry sponsored trials held a 75.9% share of all the clinical trials in Italy in 2020, when compared with the ten-year average of 73.7%. Non-industry sponsored trials accounted for a 24.1% share in 2020 as against the average of 26.3% in the last ten years.


  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry sponsored clinical trials in Italy

Oncology was the leading therapy area for industry sponsored clinical trials in Italy in 2020 with a 37.9% share, as against a five-year average of 40.3% and a ten-year average of 38.9%.

Infectious Disease held a 14.9% share in 2020, over a five-year average of 5.7% and a ten-year average of 7.6%.

Central Nervous System held a 10.6% share in 2020, compared to a five-year average of 11.6% and a ten-year average of 11.7%. Respiratory held an 8.6% share in 2020, as against a five-year average of 4.6% and a ten-year average of 4.8%.

Hematological Disorders held a 7.4% share, over a five-year average of 5.6% and a ten-year average of 5.4%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for non-industry sponsored clinical trials in Italy

Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in Italy in 2020 with a 37.3% share, as against a five-year average of 7.3% and a ten-year average of 7.4%.

Oncology held a 24.9% share in 2020, over a five-year average of 26.7% and a ten-year average of 28.5%.

Respiratory held a 23.7% share in 2020, compared to a five-year average of 3.3% and a ten-year average of 3.9%. Cardiovascular held an 11.9% share in 2020, as against a five-year average of 14.5% and a ten-year average of 15.2%.

Central Nervous System held an 11.9% share, over a five-year average of 18.6% and a ten-year average of 16.7%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase III trials lead industry sponsored clinical trials in Italy in 2020

Phase III trials held a 50.2% share of industry sponsored clinical trials in Italy in 2020, over a five-year average of 47.9% and a ten-year average of 47.7%.

Phase II trials held a 36.5% share in 2020, as against a five-year average of 37.4% and a ten-year average of 36.5%. Phase IV trials held an 8.1% share in 2020, compared to a five-year average of 9.9% and a ten-year average of 11.3%.

Phase I trials held a 5.2% share in 2020, over a five-year average of 4.8% and a ten-year average of 4.5%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead non-industry sponsored clinical trials in Italy in 2020

Phase II trials held a 54.2% share of non-industry sponsored clinical trials in Italy in 2020, over a five-year average of 58.1% and a ten-year average of 52.6%.

Phase III trials held a 23.2% share in 2020, as against a five-year average of 12.5% and a ten-year average of 15.6%. Phase IV trials held a 20.3% share, compared to a five-year average of 27.8% and a ten-year average of 29.9%.

Phase I held a 2.3% share in 2020, over a five-year average of 1.6% and a ten-year average of 1.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.